915037-63-7Relevant academic research and scientific papers
First-in-class, dual-action, 3,5-disubstituted indole derivatives having human nitric oxide synthase (nNOS) and norepinephrine reuptake inhibitory (NERI) activity for the treatment of neuropathic pain
Mladenova, Gabriela,Annedi, Subhash C.,Ramnauth, Jailall,Maddaford, Shawn P.,Rakhit, Suman,Andrews, John S.,Zhang, Dongqin,Porreca, Frank
experimental part, p. 3488 - 3501 (2012/06/17)
A family of different 3,5-disubstituted indole derivatives having 6-membered rings were designed, synthesized, and demonstrated inhibition of human nitric oxide synthase (NOS) with norepinephrine reuptake inhibitory activity (NERI). The structure-activity
3,5 - SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY
-
Page/Page column 24-25, (2009/05/28)
The present invention relates to novel 3,5-substituted indole compounds of Formula (I) having nitric oxide synthase (NOS) inhibitory activity together with inhibitory activity at the norepinephrine transporter (NET), to pharmaceutical and diagnostic compositions containing them, and to their medical use.
Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors
Deskus, Jeffrey A.,Epperson, James R.,Sloan, Charles P.,Cipollina, Joseph A.,Dextraze, Pierre,Qian-Cutrone, Jingfang,Gao, Qi,Ma, Baoqing,Beno, Brett R.,Mattson, Gail K.,Molski, Thaddeus F.,Krause, Rudolph G.,Taber, Matthew T.,Lodge, Nicholas J.,Mattson, Ronald J.
, p. 3099 - 3104 (2008/02/13)
A series of indole tetrahydropyridine and indole cyclohexenylamines was prepared, and their binding affinities at the human serotonin transporter (SERT) were determined. In particular, a nitrile substituent at the C5 position of the indole ring gave poten
Substituted indole compounds having NOS inhibitory activity
-
Page/Page column 70, (2010/11/24)
The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination w
